Cargando…
Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C
BACKGROUND & AIMS: We aimed to clarify the features of resistance-associated substitutions (RASs) after failure of multiple interferon (IFN)-free regimens in HCV genotype 1b infections. METHODS: A total of 1,193 patients with HCV for whom direct-acting antiviral (DAA) treatment had failed were e...
Autores principales: | Itakura, Jun, Kurosaki, Masayuki, Kakizaki, Satoru, Amano, Keisuke, Nakayama, Nobuaki, Inoue, Jun, Endo, Tetsu, Marusawa, Hiroyuki, Hasebe, Chitomi, Joko, Kouji, Wada, Shuichi, Akahane, Takehiro, Koushima, Youhei, Ogawa, Chikara, Kanto, Tatsuya, Mizokami, Masashi, Izumi, Namiki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424232/ https://www.ncbi.nlm.nih.gov/pubmed/32817930 http://dx.doi.org/10.1016/j.jhepr.2020.100138 |
Ejemplares similares
-
Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection
por: Fujii, Hideki, et al.
Publicado: (2022) -
Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score
por: Kaneko, Shun, et al.
Publicado: (2020) -
The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study
por: Tsuchiya, Kaoru, et al.
Publicado: (2021) -
A validation study of after direct‐acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct‐acting antiviral therapy and achieved sustained virological response
por: Tada, Toshifumi, et al.
Publicado: (2021) -
General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct‐acting antiviral therapy
por: Tada, Toshifumi, et al.
Publicado: (2022)